MARKET

BEAM

BEAM

Beam Therapeutics Inc.
NASDAQ
27.48
+0.23
+0.84%
After Hours: 27.73 +0.25 +0.91% 19:37 08/07 EDT
OPEN
27.71
PREV CLOSE
27.25
HIGH
28.35
LOW
27.13
VOLUME
1.32M
TURNOVER
--
52 WEEK HIGH
38.26
52 WEEK LOW
15.60
MARKET CAP
2.83B
P/E (TTM)
-33.7302
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), OmniAb (OABI) and Astrana Health (ASTH)
TipRanks · 2d ago
Analysts Have Lowered Expectations For Beam Therapeutics Inc. (NASDAQ:BEAM) After Its Latest Results
Simply Wall St · 2d ago
How Beam’s Wider Q2 Loss and Trial Progress Will Impact Beam Therapeutics (BEAM) Investors
Simply Wall St · 3d ago
Beam Therapeutics price target lowered to $43 from $47 at BofA
TipRanks · 3d ago
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Ultragenyx Pharmaceutical (RARE) and Beam Therapeutics (BEAM)
TipRanks · 4d ago
Evercore ISI Reaffirms Their Buy Rating on Beam Therapeutics (BEAM)
TipRanks · 4d ago
Beam Therapeutics (BEAM) On A Wider Q2 Loss And The Valuation Debate
Simply Wall St · 4d ago
Analysts Offer Insights on Healthcare Companies: Waters (WAT), Beam Therapeutics (BEAM) and Green Thumb Industries (OtherGTBIF)
TipRanks · 4d ago
More
About BEAM
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).

Webull offers Beam Therapeutics Inc stock information, including NASDAQ: BEAM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BEAM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BEAM stock methods without spending real money on the virtual paper trading platform.